Literature DB >> 2828693

Insertional mutagenesis of the Abelson murine leukemia virus genome: identification of mutants with altered kinase activity and defective transformation ability.

R W Rees-Jones1, S P Goff.   

Abstract

A library of Abelson murine leukemia virus (A-MuLV) proviral DNAs with 12- or 6-base-pair (bp) insertional mutations was constructed. The 29 mutations characterized spanned the entire protein-coding region of the provirus. We tested the effects of these mutations both on the kinase activity of the gag-abl fusion protein encoded by the provirus and on the ability of the provirus to transform NIH 3T3 fibroblasts. To simplify assessment of the mutant kinases, we expressed the A-MuLV-encoded kinase in the bacterial expression vector pATH2, resulting in production of a trpE-gag-abl fusion protein in Escherichia coli. We used an immunoprecipitation kinase assay to measure both autophosphorylation and artificial substrate phosphorylation by the mutant kinases. To assay transformation ability of the mutant proviruses, we transfected NIH 3T3 fibroblasts with the mutants and with helper virus (Moloney MuLV) by the DEAE-dextran method. Our analysis of these A-MuLV insertional mutants allows the division of the protein-coding region of the provirus into four domains: domain A (proviral bp 1068 to 1685), in which insertions have no effect on the bacterially expressed kinase, but diminish both kinase activity and transformation efficiency in fibroblasts; domain B (bp 1750 to 2078), in which insertions have no effect on the provirus; domain C (bp 2181 to 2878), the critical kinase domain, in which 12-bp or even 6-bp insertions completely inactivate the A-MuLV kinase and result in transformation-defective proviruses; and domain D (bp 2956 to 4610), the large C-terminal domain in which mutations are silent.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2828693      PMCID: PMC253657          DOI: 10.1128/JVI.62.3.978-986.1988

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Direct transformation of 3T3 cells by Abelson murine leukaemia virus.

Authors:  C D Scher; R Siegler
Journal:  Nature       Date:  1975-02-27       Impact factor: 49.962

2.  In vitro transformation of lymphoid cells by Abelson murine leukemia virus.

Authors:  N Rosenberg; D Baltimore; C D Scher
Journal:  Proc Natl Acad Sci U S A       Date:  1975-05       Impact factor: 11.205

3.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

4.  A rapid alkaline extraction procedure for screening recombinant plasmid DNA.

Authors:  H C Birnboim; J Doly
Journal:  Nucleic Acids Res       Date:  1979-11-24       Impact factor: 16.971

5.  Enchancement of the infectivity of simian virus 40 deoxyribonucleic acid with diethylaminoethyl-dextran.

Authors:  J H McCutchan; J S Pagano
Journal:  J Natl Cancer Inst       Date:  1968-08       Impact factor: 13.506

6.  Calcium-dependent bacteriophage DNA infection.

Authors:  M Mandel; A Higa
Journal:  J Mol Biol       Date:  1970-10-14       Impact factor: 5.469

7.  Abelson murine leukemia virus mutants with alterations in the virus-specific P120 molecule.

Authors:  N Rosenberg; O N Witte
Journal:  J Virol       Date:  1980-01       Impact factor: 5.103

8.  Stimulation by cyclic adenosine monophosphate of plasmid deoxyribonucleic acid replication and catabolite repression of the plasmid deoxyribonucleic acid-protein relaxation complex.

Authors:  L Katz; D T Kingsbury; D R Helinski
Journal:  J Bacteriol       Date:  1973-05       Impact factor: 3.490

9.  Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine.

Authors:  O N Witte; A Dasgupta; D Baltimore
Journal:  Nature       Date:  1980-02-28       Impact factor: 49.962

10.  Lethal effect of the Abelson murine leukemia virus transforming gene product.

Authors:  S F Ziegler; C A Whitlock; S P Goff; A Gifford; O N Witte
Journal:  Cell       Date:  1981-12       Impact factor: 41.582

View more
  8 in total

1.  Mutational analysis of the carboxyl terminus of the Moloney murine leukemia virus integration protein.

Authors:  M J Roth
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

2.  Gag influences transformation by Abelson murine leukemia virus and suppresses nuclear localization of the v-Abl protein.

Authors:  Chae-Ryun Yi; Naomi Rosenberg
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

3.  Temperature-sensitive mutants of Abelson murine leukemia virus deficient in protein tyrosine kinase activity.

Authors:  A Engelman; N Rosenberg
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

4.  Abelson murine leukemia virus induces platelet-derived growth factor-independent fibroblast growth: correlation with kinase activity and dissociation from full morphologic transformation.

Authors:  R W Rees-Jones; M Goldfarb; S P Goff
Journal:  Mol Cell Biol       Date:  1989-01       Impact factor: 4.272

5.  Targeted gene disruption of the endogenous c-abl locus by homologous recombination with DNA encoding a selectable fusion protein.

Authors:  P L Schwartzberg; E J Robertson; S P Goff
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

6.  Mutations affecting the MA portion of the v-Abl protein reveal a conserved role of Gag in Abelson murine leukemia virus (MLV) and Moloney MLV.

Authors:  Chae-ryun Yi; Naomi Rosenberg
Journal:  J Virol       Date:  2008-03-26       Impact factor: 5.103

7.  Generation of recombinant murine retroviral genomes containing the v-src oncogene: isolation of a virus inducing hemangiosarcomas in the brain.

Authors:  P Hevezi; S P Goff
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

8.  Mutational analysis of the N-linked glycosylation sites of the SU envelope protein of Moloney murine leukemia virus.

Authors:  R H Felkner; M J Roth
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.